People Roundup – 7 March 2019
Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.
You may also be interested in...
Neuraxpharm has kicked off its operations in Poland with the appointment of Wojciech Góra as general manager of its new Neuraxpharm Polska business.
Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.